Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Photopheresis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Photopheresis. Displaying page 1 of 1.
    EudraCT Number: 2012-000633-39 Sponsor Protocol Number: FEC-TH Start Date*: 2012-05-21
    Sponsor Name:Fundación para la Formación e Investigación Sanitaria
    Full Title: Extracorporeal photopheresis in liver transplantation. Clinical trial phase I/II safety and efficacy in patients with progressive withdrawal of immunosuppression.
    Medical condition: Liver transplantation more than 2 years of evolution to complications of immunosuppression.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001550-14 Sponsor Protocol Number: ECP-GVHD1 Start Date*: 2015-06-09
    Sponsor Name:Bispebjerg hospital
    Full Title: Extracorporeal Photopheresis Treatment in steroid refractory acute and chronic Graft versus Host Disease
    Medical condition: Acute and chronic Graft versus Host Disease (GVHD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002422-23 Sponsor Protocol Number: twostepala Start Date*: 2019-01-08
    Sponsor Name:Akershus University Hospital
    Full Title: Extracorporeal photopheresis of patients with Crohns disease using 5- aminolevulinic acid.
    Medical condition: Crohns disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004806-14 Sponsor Protocol Number: TKS-2014-001 Start Date*: Information not available in EudraCT
    Sponsor Name:Therakos, Inc.
    Full Title: Single-Arm Study to Assess the Efficacy of UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients with Steroid-Refractory Acute ...
    Medical condition: Acute graft-versus-host disease (aGvHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) GB (Completed) IT (Completed) ES (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022780-35 Sponsor Protocol Number: 10-005 Start Date*: 2011-07-06
    Sponsor Name:THERAKOS, Inc.
    Full Title: A Randomized Controlled Study of Extracorporeal Photopheresis (ECP) Therapy with UVADEX™ for the Treatment of Patients with Moderate to Severe Chronic Graft-versus-Host Disease (cGvHD)
    Medical condition: Chronic graft-versus-host disease (cGvHD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018651 Graft versus host disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) AT (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004432-38 Sponsor Protocol Number: CINC424D2301 Start Date*: 2017-10-11
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogeneic stem cel...
    Medical condition: corticosteroid refractory chronic Graft vs Host Disease
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10072158 Chronic graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10072159 Chronic graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    20.1 10021428 - Immune system disorders 10072160 Chronic graft versus host disease in liver PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) AT (Completed) ES (Ongoing) BE (Completed) DK (Completed) NL (Completed) IT (Completed) FR (Completed) PT (Completed) HU (Completed) PL (Completed) BG (Completed) NO (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2008-007794-20 Sponsor Protocol Number: Acute GVHD - ECP Start Date*: 2009-06-10
    Sponsor Name:AKH Wien, Klinik für Innere Medizin I, Onkologie
    Full Title: A randomized controlled open-label multicenter phase II study for initial treatment of acute graft-versus-host disease with extracorporeal photopheresis and corticosteroids or corticosteroids alone
    Medical condition: Patients with newly diagnosed acute GVHD grades II to IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003286-26 Sponsor Protocol Number: PCYC-1140-IM Start Date*: 2017-04-18
    Sponsor Name:Pharmacyclics LLC
    Full Title: A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Dis...
    Medical condition: Chronic Graft Versus Host Disease (cGVHD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066261 Chronic graft versus host disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) AT (Completed) HR (Completed) IT (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-005162-22 Sponsor Protocol Number: PSS2017/PCE-aGVHD-RUBIO/VS Start Date*: 2018-05-22
    Sponsor Name:CHRU de Nancy
    Full Title: A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporal photopheresis (ECP) as first-line treatment of standard risk Grade II acute graft-v...
    Medical condition: Standard II acute graft-versus-host disease following allogeneic stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-004766-17 Sponsor Protocol Number: 0761-010 Start Date*: 2013-07-23
    Sponsor Name:Kyowa Hakko Kirin Pharma, Inc.
    Full Title: Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (mogamulizumab) Versus Vorinostat in Subjects with Previously Treated Cutaneous T-Cell Lymphoma (CTCL)
    Medical condition: Treatment of subjects with previously treated cutaneous T-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10011679 Cutaneous T-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) NL (Completed) DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002073-26 Sponsor Protocol Number: 1125-ECIR Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Center - University of Freiburg
    Full Title: Phase 1/2 Trial to determine the safety and efficacy of Extracorporeal photopheresis as treatment for steroid-refractory immune related adverse events after immune checkpoint inhibitor therapy
    Medical condition: Immune related adverse events induced by treatment with immune checkpoint inhibitors (monoclocanl antibodies against PD-1, PD-L1 or CTLA-4)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10043408 Therapeutic agent toxicity LLT
    26.1 10018065 - General disorders and administration site conditions 10067033 Drug side effect LLT
    24.0 10018065 - General disorders and administration site conditions 10061623 Adverse drug reaction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000894-22 Sponsor Protocol Number: MAGIC-HR-ECP Start Date*: 2019-12-10
    Sponsor Name:Department of Stem Cell Transplantation - University Medical Center Hamburg-Eppendorf
    Full Title: Phase II multicenter study of extracorporeal photopheresis with UvadexTM plus standard steroid treatment for high risk acute Graft-versus-Host Disease
    Medical condition: New onset high risk acute GvHD following allogeneic SCT
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000807-99 Sponsor Protocol Number: 4SC-201-6-2015 Start Date*: 2016-09-15
    Sponsor Name:4SC AG
    Full Title: A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) ...
    Medical condition: Advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028508 Mycosis fungoides/Sezary syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) AT (Completed) BE (Completed) PL (Completed) GR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004537-20 Sponsor Protocol Number: 0761-016 Start Date*: 2021-07-22
    Sponsor Name:Kyowa Kirin Inc.
    Full Title: Open-Label, Phase 2 Study to Assess the Safety of Mogamulizumab Given Every 4 Weeks Following Induction in Participants with Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL)
    Medical condition: Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) - Mycosis fungoides and Sezary syndrome
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004864 10028510 Mycosis fungoides/Sezary syndrome recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000862-31 Sponsor Protocol Number: GLAS Start Date*: 2017-09-28
    Sponsor Name:Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)
    Full Title: A phase Ib/IIa pilot trial of the oral Hedgehog Signalling Inhibitor, Glasdegib, in Patients with sclerotic chronic graft-versus-host disease refractory to second-line treatment
    Medical condition: Adult patiens with sclerotic chronic graft-versus-host disease refractory to second-line treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000109195 10074474 Transplantation complications HLT
    20.0 100000022080 10067862 Allogeneic stem cell transplantation LLT
    20.0 10022117 - Injury, poisoning and procedural complications 10074555 Transplantation complication PT
    20.0 100000020501 10018653 Graft-versus-host disease LLT
    20.0 100000022080 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004847-35 Sponsor Protocol Number: PredEver_first Start Date*: 2012-09-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -
    Medical condition: chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018799 GVHD LLT
    14.1 10021428 - Immune system disorders 10063109 Transfusion associated GVHD LLT
    14.1 10021428 - Immune system disorders 10068907 CGVHD LLT
    14.1 10021428 - Immune system disorders 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 10:30:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA